One of London’s largest public transport operators has selected the Intelligent Fingerprinting Drug Screening System to support its commitment to safety, efficiency, and modernization across its network.
The contract covers 14 operational sites across Greater London and a workforce of over 4,400 employees. The operator’s multi-garage bus network carries more than one million passengers each day, with a fleet of over 1,400 low-emission buses, including hybrid, electric, and hydrogen-powered vehicles.
Rapid, Scalable Testing for Safety-Critical Environments
Our fingerprint sweat-based drug testing technology enables quick and reliable workplace drug testing at scale, helping reduce downtime and keep operations running smoothly. For public transport providers, where service interruptions can have widespread impacts, minimising time away from duty is critical.
Harry Simeonidis, President and CEO, explained:
“We offer a system that supports rapid drug testing at scale, meaning less people out of action for less time. This minimises financial loss associated with long wait times and improves overall workforce efficiency. The rapidly rising popularity of our solution is testament to the many benefits it offers businesses of all sizes; from a greater suggestion of impairment and reduced risk to cost savings and a more dignified approach.”
A Modern Approach to Workforce Safety
The decision to implement our system is part of the operator’s broader investment in people, infrastructure, and safety. Backed by purpose-built engineering and logistics facilities, they represent a forward-thinking leader in the transport sector, embracing solutions that keep employees, passengers, and the public safe.
Growing Global Reach
Intelligent Fingerprinting’s technology is now used by more than 450 accounts in 24 countries, supported by 18 distribution partners. While we continue to expand across the UK, our presence is also growing in Europe, the Middle East and Africa, Asia Pacific, and the United States. Securing U.S. Food and Drug Administration (FDA) clearance remains a priority, with U.S. market entry planned for 2025.
